Sen. Sheldon Whitehouse Sells Off Shares of Amgen Inc. (NASDAQ:AMGN)

Posted by Stuart Ham on Sep 5th, 2026

Senator Sheldon Whitehouse (Democratic-Rhode Island) recently sold shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on September 02nd, the Senator disclosed that they had sold between $1,001 and $15,000 in Amgen stock on August 12th.

Senator Sheldon Whitehouse also recently made the following trade(s):

Sold $15,001 – $50,000 in shares of NVIDIA (NASDAQ:NVDA) on 8/13/2026.
Sold $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 8/13/2026.
Sold $1,001 – $15,000 in shares of Lam Research (NASDAQ:LRCX) on 8/13/2026.
Sold $1,001 – $15,000 in shares of Lowe’s Companies (NYSE:LOW) on 7/20/2026.
Sold $15,001 – $50,000 in shares of NVIDIA (NASDAQ:NVDA) on 6/30/2026.
Sold $1,001 – $15,000 in shares of Crown Castle (NYSE:CCI) on 6/25/2026.
Purchased $15,001 – $50,000 in shares of Coherent (NYSE:COHR) on 6/25/2026.
Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 6/25/2026.
Sold $15,001 – $50,000 in shares of Apple (NASDAQ:AAPL) on 6/24/2026.

Amgen Trading Down 1.6%

Shares of AMGN stock opened at $437.23 on Friday. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $447.03. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The stock’s 50 day simple moving average is $397.39 and its two-hundred day simple moving average is $367.15. The company has a market cap of $236.38 billion, a PE ratio of 27.17, a price-to-earnings-growth ratio of 3.20 and a beta of 0.43.

Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. The company had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.Amgen’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Research analysts predict that Amgen Inc. will post 22.97 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s payout ratio is presently 62.65%.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Repatha data could expand its addressable market. Amgen reported that Repatha reduced all-cause mortality by 20% in a prespecified analysis of the Phase 3 VESALIUS-CV trial, which studied more than 12,000 high-risk adults who had not previously experienced a heart attack or stroke. Earlier use could support broader adoption of the cardiovascular drug. Amgen Repatha VESALIUS-CV article
Positive Sentiment: MariTide retains a potential convenience advantage in obesity treatment. Amgen’s investigational therapy could require less-frequent dosing than competing treatments from Eli Lilly and Novo Nordisk. That feature may help differentiate MariTide if its clinical and regulatory profile supports approval, although competition in the market remains intense. Amgen MariTide obesity article
Neutral Sentiment: Shares had recently approached a 52-week high. Recent strength followed better-than-expected quarterly earnings and raised 2026 guidance, but the stock’s elevated valuation and gains left it more vulnerable to profit-taking when adverse regulatory news emerged. Amgen stock and 2026 guidance article
Negative Sentiment: U.K. action against Tavneos intensified regulatory risk. The U.K. regulator suspended Tavneos for new patients and indicated a path toward revoking its authorization in March 2027, saying the drug’s benefit-risk balance was no longer favorable and that its pivotal efficacy study could not be relied upon. This compounds the FDA’s April proposal to withdraw U.S. approval over effectiveness, application-disclosure and liver-safety concerns, raising the possibility of broader loss of value for the drug. Amgen Tavneos regulatory pressure article
Negative Sentiment: Insider selling added a modest sentiment headwind. Reported insider transactions showed seven sales and no purchases over the past six months, though these trades are less significant than the Tavneos developments. Amgen trading disclosures article

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of recent analyst reports. Royal Bank Of Canada lifted their price target on shares of Amgen from $370.00 to $400.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. The Goldman Sachs Group set a $389.00 price objective on shares of Amgen in a research note on Friday, June 5th. Mizuho upped their target price on Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a research note on Tuesday, August 18th. Weiss Ratings raised Amgen from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 6th. Finally, Sanford C. Bernstein boosted their price objective on Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $381.68.

Get Our Latest Stock Report on Amgen

Insiders Place Their Bets

In related news, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 6,222 shares of company stock valued at $2,540,926 over the last 90 days. 0.85% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Anfield Capital Management LLC boosted its stake in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares in the last quarter. Dogwood Wealth Management LLC lifted its holdings in Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares during the period. Tower View Wealth Management LLC boosted its position in Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 63 shares in the last quarter. Manning & Napier Advisors LLC increased its holdings in shares of Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares during the period. Finally, Evergreen Advisors LLC bought a new position in shares of Amgen in the 1st quarter worth $37,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

About Senator Whitehouse

Sheldon Whitehouse (Democratic Party) is a member of the U.S. Senate from Rhode Island. He assumed office on January 3, 2007. His current term ends on January 3, 2031.

Whitehouse (Democratic Party) ran for re-election to the U.S. Senate to represent Rhode Island. He won in the general election on November 5, 2024.

About Amgen

(Get Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.